Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab effect on Leptomeningeal Inflammation in MS
NCT05208840Phase 4Withdrawn
- Sponsor
- Roche
- Start
- Sep 2023
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of ocrelizumab in progressive multiple sclerosis (PMS) (2 arms), sponsored by Roche. Primary endpoint: Number of LMCE foci at Month 24. Planned start Sep 2023; status: withdrawn.
02
Drugs
ocrelizumab
03
Conditions
progressive multiple sclerosis (PMS)
Beyond the preview
Go deeper on NCT05208840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05208840.